Results 121 to 130 of about 20,430,225 (174)

Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma. [PDF]

Can Urol Assoc J
Teishima J, Hara T, Tobe T, Hirata J, Ueki H, Wakita N, Shiraishi Y, Okamura Y, Bando Y, Terakawa T, Furukawa J, Harada KI, Nakano Y, Fujisawa M.   +13 more
europepmc   +1 more source

The long-term outcomes of local tumor destruction versus partial nephrectomy for cT1a non-clear cell renal cell carcinoma and development of prognostic nomograms. [PDF]

J Cancer Res Clin Oncol
Qiu J, Deng R, Zhao Z, Tian P, Zhou J.
europepmc   +1 more source

Adjuvant Therapy for Non–Clear Cell Renal Cell Carcinoma—The Ascent Continues

JAMA Network Open
openaire   +2 more sources

Surgical Outcomes and Genomic Insights of Nonclear Cell Renal Cell Carcinoma With Synchronous and Metachronous Nodal Disease. [PDF]

Urol Pract
Eismann L, Zucker M, Dawidek MT, Reese SW, Calderon LP, Aulitzky A, Stief CG, Coleman JA, Kotecha RR, Carlo M, Chen Y, Reznik E, Russo P, Hakimi AA.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Combination therapies in non-clear-cell renal cell carcinoma

The Lancet Oncology, 2023
We investigate the 1/Q^2 power-suppressed corrections to structure functionsin the flavour-singlet channel of deep inelastic lepton scattering arising fromrenormalon insertions into an initial-state gluon, as obtained using thedispersive approach. The pinch technique is used as a convenient tool in theseparation of contributions.
ÖZET, AHMET, ÖZDEMİR, NURİYE, ASLAN, VOLKAN, YAZICI, OZAN   +3 more
openaire   +3 more sources

Chemotherapy for Non–Clear-Cell Renal Cell Carcinoma

Clinical Genitourinary Cancer, 2006
Clear-cell carcinoma is the most common histopathologic subtype of kidney tumors. Consequently, clinical trials for advanced-stage kidney cancer have focused on patients with clear-cell carcinoma and not on the less common subtypes, including papillary, chromophobe, collecting-duct carcinoma, and sarcomatoid-variant tumors.
Kevin A, David, Matthew I, Milowsky, David M, Nanus   +2 more
openaire   +2 more sources

Non–Clear Cell Renal Cell Carcinomas: From Shadow to Light

Journal of Clinical Oncology, 2018
Non–clear cell renal cell carcinomas (RCCs) account for up to 25% of kidney cancers and encompass distinct diseases with distinct pathologic features, different molecular alterations, and various patterns of response to systemic therapies. Recent advances in molecular biology and large collaborative efforts helped to better define the oncogenic ...
Albiges, L, Flippot, R, Rioux-Leclercq, N, Choueiri, Tk.   +3 more
openaire   +3 more sources